News
Public · Published
IDEXX Laboratories Q3 revenue beats estimates, lifts FY profit outlook
IDEXX Laboratories said third-quarter revenue rose 10% and beat analyst expectations, while earnings per share increased 18% to $4.01. It raised its 2026 revenue and earnings outlook, citing strong recurring revenue growth, but lowered its operating margin forecast.
Published:
Updated:
What happened
IDEXX Laboratories said third-quarter revenue rose 10% and beat analyst expectations, while earnings per share increased 18% to $4.01. It raised its 2026 revenue and earnings outlook, citing strong recurring revenue growth, but lowered its operating margin forecast.
Confirmed
Global impact / market context
Higher recurring diagnostic sales, customer gains and new products are supporting IDEXX’s growth outlook. However, the lower operating margin forecast means the company expects to keep less of each sales dollar after operating costs, tempering the profit benefit from higher projected revenue.
Analyst inference
Recurring revenue growth, customer gains and new diagnostic products can support sales by encouraging ongoing testing and instrument use. However, the lower operating margin outlook suggests costs may absorb more of each sales dollar, tempering the benefit of the stronger revenue and profit forecast.
Analyst inference
What to watch
- Track whether recurring diagnostic sales keep growing through same-store testing volume, customer gains and a larger instrument base, the drivers the company cited for the quarter. Analyst inference
- Compare future results with the raised 2026 revenue outlook and earnings-per-share guidance; sustained growth would support the company’s higher profit expectations. Confirmed
- Watch whether operating margin, the share of revenue remaining after operating costs, reaches the lowered 2026 outlook, since a shortfall could constrain profit growth. Analyst inference
Evidence
- Original source link unavailable